Holzer & Holzer
Law Firms & Legal Services · Georgia, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
211 Perimeter Center Pkwy NE Ste 1010, A...Phone Number
(770) 392-0090Website
www.holzerlaw.comRevenue
<$5 MillionIndustry
About Holzer & Holzer
Holzer & Holzer Org Chart
Is Holzer & Holzer your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Holzer & Holzer had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Holzer & Holzer, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Holzer & Holzer recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Holzer & Holzer
Check if Holzer & Holzer has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Holzer & Holzer has new funding data
Check out if Holzer & Holzer is spiking on competitors!
Product Launch: Get notified when Holzer & Holzer launches new products
Recommended Actions
Find VP level buyers at Holzer & Holzer
Find 3 more new buyers
Compare Similar Companies to Holzer & Holzer
Compare insights from companies similar to Holzer & Holzer, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Holzer & Holzer is experiencing very low activity levels compared to other companies in the Law Firms & Legal Services sector.
What does this means?
Holzer & Holzer is drawing exceptional interest within the Law Firms & Legal Services industry, suggesting notable developments or strong market momentum, learn more about Holzer & Holzer.
Holzer & Holzer Tech Stack
A closer look at the technologies used by Holzer & Holzer
Holzer & Holzer News & Media
POET INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of the June 29, 2026 Lead Plaintiff Deadline in the POET Technologies Inc. Securities Class Action
ATLANTA, June 16, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against POET Technologies Inc. (“POET”) (NASDAQ: POET). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts regarding POET’s business, operations, and prospects, including allegations that: (1) POET misrepresented its tax status due to it likely being deemed a passive foreign investment company (or “PFIC”) under U.S. tax laws which, ifZSPC INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of the June 22, 2026 Lead Plaintiff Deadline in the zSpace, Inc. Securities Class Action
ATLANTA, June 16, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against zSpace, Inc. (“zSpace” or the “Company”) (NASDAQ: ZSPC). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts in the Registration Statement issued in connection with zSpace’s Initial Public Offering (“IPO”), including allegations that: (1) before zSpace even filed its form S-1, a certain purchaser of Series E and Series F prefNMRA INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Neumora Therapeutics, Inc.
ATLANTA, June 15, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (NASDAQ: NMRA) complied with federal securities laws. On June 15, 2026, Neumora announced that “the Phase 3 KOASTAL-2 and -3 studies of navacaprant for the treatment of major depressive disorder (MDD) did not achieve statistical significance on the primary or key secondary endpoints.” Neumora is discontinuing development of navacaprant and reducing itsELTX INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Elicio Therapeutics, Inc.
ATLANTA, June 15, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Elicio Therapeutics, Inc. (“Elicio” or the “Company”) (NASDAQ: ELTX) complied with federal securities laws. On June 15, 2026, Elicio announced that its Phase 2 AMPLIFY-7P trial for the pancreatic cancer therapy ELI-002 7P missed its primary endpoint. The price of the Company’s stock dropped following this news.
Top Law Firms & Legal Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Holzer & Holzer
Holzer & Holzer is a top securities law firm that specializes in representing investors in class action litigation under federal securities laws. Established in 2000, the firm is dedicated to protecting investors' rights and pursuing corporate governance reform. With a reputation for excellence in federal and state courts, their experienced attorne... Read More